

Michigan Pharmacy and Therapeutics Committee
Cardiac Workgroup
Review of Preferred Drug List (P&T) Classes
February 2008

Following discussion and review, the workgroup recommends the following to the full P&T and to the Department:

Cardiac Medications

ACE Inhibitors

No change to the current classification of the drugs in this class

Antihypertensive Combinations-ACEI-CCB

No change to the current classification of the drugs in this class

Angiotensin Receptor Antagonists

No change to the current classification of the drugs in this class

Direct Renin Inhibitors

No change to the current classification of the drug in this class

Beta blockers

No change to the current classification of the drugs in this class

Calcium Channel Blockers-Dihydropyridine

No change to the current classification of the drugs in this class

Calcium Channel Blockers-Non-Dihydropyridines

No change to the current classification of the drugs in this class

Lipotropic-Antihypertensive Combination

No change to the current classification of the drug in this class

Lipotropics-Non Statins: Fibric Acid Derivatives

No change to the current classification of the drugs in this class

Lipotropics: Non Statins

No change to the current classification of the drugs in this class

Lipotropics: Statins

Create an electronic edit at point of sale to allow Advicor prescriptions without formal prior authorization if the patient has been on either lovastatin or niacin product in the past

No change to the other drug classifications in this class

Lipotropics: Niacin Derivatives

No change to the current classification of the drugs in this class

Lipotropics: Other

Remove prior authorization from Lovaza (Omacor)

Keep Zetia available without prior authorization at this time

In addition, the workgroup recommended creating a new class of antihypertensives to include the CCB-ARA products, and to add Exforge to this class without prior authorization as a new drug to be reviewed at the March meeting.